Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Sequential RCHOP, Radioimmunotherapy and Rituximab Maintenance Improves Early Outcomes in Advanced Stage Follicular Lymphoma: 5 Year Outcomes from SWOG 0801

Paul M. Barr, Hongli Li, PhD, Richard Burack, MD PhD, Michael LeBlanc, PhD, Sonali M. Smith, MD, Ajay K. Gopal, MD, Justin D. Floyd, DO, Daniel O. Persky, MD, Oliver Press, MD PhD, Richard I. Fisher, MD, Jonathan W. Friedberg, MD

Blood (2016) 128 (22): 614.

https://doi.org/10.1182/blood.V128.22.614.614

Published: 2016

Journal Articles

Continued Excellent Outcomes in Previously Untreated Follicular Lymphoma Patients after Treatment with CHOP Plus Rituximab or CHOP Plus (131) Iodine-Tositumomab - Long Term Follow-up of Phase III Randomized Study SWOG S0016

Mazyar Shadman, MD MPH, Hongli Li, PhD, Lisa Rimsza, MD, John P. Leonard, MD, Mark S Kaminski, MD, Rita M Braziel, MD, Catherine M. Spier, MD, Ajay K Gopal, MD, David G Maloney, MD PhD, Bruce Cheson, MD, Shaker Dakhil, MD FACP, Michael LeBlanc, PhD, Sonali M. Smith, MD, Richard I. Fisher, MD, Jonathan W. Friedberg, MD, Oliver Press, MD PhD

Blood (2016) 128 (22): 616.

https://doi.org/10.1182/blood.V128.22.616.616

Published: 2016

Journal Articles

Polatuzumab Vedotin Combined with Obinutuzumab for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma: Preliminary Safety and Clinical Activity of a Phase Ib/II Study

Tycel Phillips, MD, Mark Brunvand, MD, Andy Chen, MD PhD, Oliver Press, MD PhD, James Essell, MD, Annalisa Chiappella, MD, Catherine Diefenbach, MD, Surai Jones, MS Biostat, Jamie Hirata, PharmD, Ian W. Flinn, MD PhD

Blood (2016) 128 (22): 622.

https://doi.org/10.1182/blood.V128.22.622.622

Published: 2016

Journal Articles

Fludarabine, Cyclophosphamide, Rituximab (FCR) and Vorinostat Followed By Rituximab and Vorinostat Maintenance Therapy in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) - Final Results of a Phase I/II Study

Mazyar Shadman, MD MPH, Ajay K Gopal, MD, Oliver Press, MD PhD, David G. Maloney, MD PhD, Raya Mawad, MD, Troy Wadsworth, MD, Trevor W. Dennie, MD, Karl Schultheiss, MD, Kiarash Kojouri, MD MPH, Britt E Kammerer, John M. Pagel, MD PhD

Blood (2016) 128 (22): 4396.

https://doi.org/10.1182/blood.V128.22.4396.4396

Published: 2016

Journal Articles

Impact of Increased Body Weight on Acute Toxicity and Outcome of Autologous Stem Cell Transplantation for Non-Hodgkin’s Lymphoma: A Southwest Oncology Group Analysis.

Patrick Stiff, MD, Joseph Unger, MS, Stephen Forman, MD, Michael LeBlanc, PhD, Thomas Miller, MD, Oliver Press, MD, John Thompson, MD, Richard Fisher, MD

Blood (2004) 104 (11): 352.

https://doi.org/10.1182/blood.V104.11.352.352

Published: 2004

NARROW

Sequential RCHOP, Radioimmunotherapy and Rituximab Maintenance Improves Early Outcomes in Advanced Stage Follicular Lymphoma: 5 Year Outcomes from SWOG 0801

Continued Excellent Outcomes in Previously Untreated Follicular Lymphoma Patients after Treatment with CHOP Plus Rituximab or CHOP Plus (131) Iodine-Tositumomab - Long Term Follow-up of Phase III Randomized Study SWOG S0016

Polatuzumab Vedotin Combined with Obinutuzumab for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma: Preliminary Safety and Clinical Activity of a Phase Ib/II Study

Fludarabine, Cyclophosphamide, Rituximab (FCR) and Vorinostat Followed By Rituximab and Vorinostat Maintenance Therapy in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) - Final Results of a Phase I/II Study

Impact of Increased Body Weight on Acute Toxicity and Outcome of Autologous Stem Cell Transplantation for Non-Hodgkin’s Lymphoma: A Southwest Oncology Group Analysis.

Email alerts

ASH Publications

American Society of Hematology

Sequential RCHOP, Radioimmunotherapy and Rituximab Maintenance Improves Early Outcomes in Advanced Stage Follicular Lymphoma: 5 Year Outcomes from SWOG 0801

Continued Excellent Outcomes in Previously Untreated Follicular Lymphoma Patients after Treatment with CHOP Plus Rituximab or CHOP Plus (131) Iodine-Tositumomab - Long Term Follow-up of Phase III Randomized Study SWOG S0016

Polatuzumab Vedotin Combined with Obinutuzumab for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma: Preliminary Safety and Clinical Activity of a Phase Ib/II Study

Fludarabine, Cyclophosphamide, Rituximab (FCR) and Vorinostat Followed By Rituximab and Vorinostat Maintenance Therapy in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) - Final Results of a Phase I/II Study

Impact of Increased Body Weight on Acute Toxicity and Outcome of Autologous Stem Cell Transplantation for Non-Hodgkin’s Lymphoma: A Southwest Oncology Group Analysis.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only